R & D

iNtRON has announced the completion of an efficacy evaluation study of BAL200

SynaptixBio has received FDA Rare Paediatric Disease designation to develop new treatments for rare disease TUBB4a leukodystropy

TheracosBio has announced that bexaglifozin has been approved by the FDA for the treatment of adult patients with type 2 diabetes, despite originally being indicated for cats with diabetes

J&J's Ethicon has announced that it has undertaken its first robot-assisted kidney stone removal using its Monarch Platform

The University of Plymouth has co-authored a new study, published in The Lancet, which shows how an asthma drug, commercially known as Relvar Ellipta, was more effective than patients’ usual care at improving their asthma control.

Biotech company Guardant Health has announced that its blood test-based cancer screening technique appears to be effective: the liquid biopsy detected cases of colorectal cancer in 83% of patients who had the disease. It also correctly detected people who did not have colorectal cancer 90% of the time. However, some investors are disappointed with the technology’s ability to detect precancerous tumours.

US-based biotech companies Belharra Therapeutics and Genentech have announced a multi year partnership to lead the discovery and development of small molecule medicines in multiple therapeutic areas, including oncology, immune-oncology, autoimmune and neurodegenerative diseases.

Promising results announced from human trial of new HIV vaccine

Amgen Inc’s new obesity drug has appeared promising in its small phase 1 trial, meaning it will be able to go ahead with a larger mid-stage trial in 2023. The trial demonstrated that patients were able to maintain their weight loss for 70 days following the highest dose of the drug, known as AMG133.

Ryvu Therapeutics, a clinical-stage oncology therapeutics development company, has announced a collaboration with BioNTech, which will consist of two parts: multi-target research into several small molecule immunotherapy programmes and an exclusive licence agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.

FDA approvals to WISE for neuromonitoring device

Data from a Phase III clinical trial has shown that the Respiratory Syncytial Virus (RSV) vaccine is 85.7% effective when administered to patients 60 years and older, burgeoning hopes for a first bivalent RSV vaccine candidate.